Takeda amyloidosis therapy granted breakthrough status by US FDA
Takeda’s investigational, oral proteasome inhibitor, ixazomib (MLN9708), for the treatment of relapsed or refractory systemic light-chain (AL) amyloidosis, has received Breakthrough Therapy... Read More